Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-05-07

FDA Approved: REXULTI — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rexulti (brexpiprazole) by Otsuka America Pharmaceutical, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REXULTI (brexpiprazole)

Snippet

SUPPL AP for REXULTI (BREXPIPRAZOLE)